Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cytochrome P450, family 3, subfamily A, polypeptide 4 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | cytochrome P450 | cytochrome P450, family 3, subfamily A, polypeptide 4 | 502 aa | 492 aa | 24.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | hypothetical protein | 0.0069 | 0.7416 | 0.7416 |
Brugia malayi | hypothetical protein | 0.0038 | 0.3123 | 0.3123 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | 0.0088 | 1 | 1 |
Echinococcus granulosus | jun protein | 0.0088 | 1 | 1 |
Mycobacterium ulcerans | cytochrome P450 185A4 Cyp185A4 | 0.0015 | 0 | 0.5 |
Leishmania major | cytochrome p450-like protein | 0.0015 | 0 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | 0.0088 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0015 | 0 | 0.5 |
Trypanosoma brucei | cytochrome P450, putative | 0.0015 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0071 | 0.7746 | 1 |
Onchocerca volvulus | 0.0069 | 0.7416 | 0.5 | |
Entamoeba histolytica | hypothetical protein | 0.0038 | 0.3123 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0038 | 0.3123 | 0.5 |
Schistosoma mansoni | jun-related protein | 0.0071 | 0.7746 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0038 | 0.3123 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0038 | 0.3123 | 0.5 |
Echinococcus multilocularis | jun protein | 0.0088 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0086 | 0.967 | 1 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0015 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp1a2 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2d6 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | = 6.309573445 uM | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp3a4 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference |
AC50 (functional) | = 39.81071706 uM | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c19 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference |
Potency (ADMET) | = 6.3096 um | PUBCHEM_BIOASSAY: qHTS Assay for Activators of Cytochrome P450 3A4. (Class of assay: confirmatory) [Related pubchem assays: 410 ] | ChEMBL. | No reference |
Potency (ADMET) | = 6.3096 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4. (Class of assay: confirmatory) [Related pubchem assays: 410 ] | ChEMBL. | No reference |
Potency (ADMET) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19. (Class of assay: confirmatory) [Related pubchem assays: 410 ] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.